Bacillus Coagulans: a Viable Adjunct Therapy for Relieving Symptoms of Rheumatoid Arthritis According to a Randomized, Controlled Trial

Overview

Journal BMC Complement Altern Med

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2010 Jan 14

PMID 20067641

Citations 58

Authors

David R Mandel

Katy Eichas

Judith Holmes

Affiliations

Soon will be listed here.

Abstract

Background: Lactic acid-producing bacteria (LAB) probiotics demonstrate immunomodulating and anti-inflammatory effects and the ability to lessen the symptoms of arthritis in both animals and humans. This randomized, double-blind, placebo-controlled, parallel-design, clinical pilot trial was conducted to evaluate the effects of the LAB probiotic preparation, Bacillus coagulans GBI-30, 6086, on symptoms and measures of functional capacity in patients with rheumatoid arthritis (RA) in combination with pharmacological anti-arthritic medications.

Methods: Forty-five adult men and women with symptoms of RA were randomly assigned to receive Bacillus coagulans GBI-30, 6086 or placebo once a day in a double-blind fashion for 60 days in addition to their standard anti-arthritic medications. Arthritis activity was evaluated by clinical examination, the American College of Rheumatology (ACR) criteria, the Stanford Health Assessment Questionnaire Disability Index (HAQ-DI), and laboratory tests for erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).

Results: Subjects who received Bacillus coagulans GBI-30, 6086 experienced borderline statistically significant improvement in the Patient Pain Assessment score (P = .052) and statistically significant improvement in Pain Scale (P = .046) vs placebo. Compared with placebo, Bacillus coagulans GBI-30, 6086 treatment resulted in greater improvement in patient global assessment and self-assessed disability; reduction in CRP; as well as the ability to walk 2 miles, reach, and participate in daily activities. There were no treatment-related adverse events reported throughout this study.

Conclusions: Results of this pilot study suggest that adjunctive treatment with Bacillus coagulans GBI-30, 6086 LAB probiotic appeared to be a safe and effective for patients suffering from RA. Because of the low study population size, larger trials are needed to verify these results.

Trial Registration: ACTRN12609000435280.

Citing Articles

Gut Microbiota Modulation: A Novel Strategy for Rheumatoid Arthritis Therapy.

Chasov V, Gilyazova E, Ganeeva I, Zmievskaya E, Davletshin D, Valiullina A Biomolecules. 2025; 14(12.

PMID: 39766360 PMC: 11674688. DOI: 10.3390/biom14121653.

5-Methyltetrahydrofolate and aqueous extract of () ameliorate diabetes and associated complications in STZ-induced diabetic rats.

Pathikkal A, Bhaskar T, Prasanthan A, Haritha P, Puthusseri B, Rudrappa S 3 Biotech. 2024; 15(1):15.

PMID: 39711918 PMC: 11655854. DOI: 10.1007/s13205-024-04170-9.

Can we modulate the gut microbiome to enhance DMARD efficacy in rheumatoid arthritis?.

Blank R, Nayak R, Scher J Semin Arthritis Rheum. 2024; 70S:152583.

PMID: 39551674 PMC: 11761361. DOI: 10.1016/j.semarthrit.2024.152583.

Influences of tea consumption on self-rated health and life satisfaction among older adults: Evidence from the CLHLS.

Zou M, Sun C, Yang M, Li C, Wang S, Zheng D Psych J. 2024; 14(1):62-73.

PMID: 39462173 PMC: 11787876. DOI: 10.1002/pchj.807.

Heyndrickxia coagulans LMG S-24828 Is a Safe Probiotic Strain Capable of Germinating in the Human Gut.

Duncan R, Mantegazza G, Gargari G, Pierallini E, Russo R, Guglielmetti S Probiotics Antimicrob Proteins. 2024; .

PMID: 39432229 DOI: 10.1007/s12602-024-10383-4.

References

Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38(6):727-35. DOI: 10.1002/art.1780380602. View

Casula G, Cutting S . Bacillus probiotics: spore germination in the gastrointestinal tract. Appl Environ Microbiol. 2002; 68(5):2344-52. PMC: 127533. DOI: 10.1128/AEM.68.5.2344-2352.2002. View

Arend W . Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum. 2001; 45(1):101-6. DOI: 10.1002/1529-0131(200102)45:1<101::AID-ANR90>3.0.CO;2-7. View

Smolen J, Steiner G . Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003; 2(6):473-88. DOI: 10.1038/nrd1109. View

Sheil B, McCarthy J, OMahony L, Bennett M, Ryan P, Fitzgibbon J . Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut. 2004; 53(5):694-700. PMC: 1774028. DOI: 10.1136/gut.2003.027789. View

Sheih Y, Chiang B, Wang L, Liao C, Gill H . Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr. 2001; 20(2 Suppl):149-56. DOI: 10.1080/07315724.2001.10719027. View

van den Broek M, van Bruggen M, Koopman J, Hazenberg M, van den Berg W . Gut flora induces and maintains resistance against streptococcal cell wall-induced arthritis in F344 rats. Clin Exp Immunol. 1992; 88(2):313-7. PMC: 1554307. DOI: 10.1111/j.1365-2249.1992.tb03079.x. View

Sartor R . Review article: Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther. 1998; 11 Suppl 3:17-22; discussion 22-3. DOI: 10.1111/j.1365-2036.1997.tb00805.x. View

Helmick C, Felson D, Lawrence R, Gabriel S, Hirsch R, Kwoh C . Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008; 58(1):15-25. DOI: 10.1002/art.23177. View

10.

Kano H, Kaneko T, Kaminogawa S . Oral intake of Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 prevents collagen-induced arthritis in mice. J Food Prot. 2002; 65(1):153-60. DOI: 10.4315/0362-028x-65.1.153. View

11.

So J, Kwon H, Lee C, Yi H, Park J, Lim S . Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol Immunol. 2008; 45(9):2690-9. DOI: 10.1016/j.molimm.2007.12.010. View

12.

Marco M, Pavan S, Kleerebezem M . Towards understanding molecular modes of probiotic action. Curr Opin Biotechnol. 2006; 17(2):204-10. DOI: 10.1016/j.copbio.2006.02.005. View

13.

Vaarala O . Immunological effects of probiotics with special reference to lactobacilli. Clin Exp Allergy. 2003; 33(12):1634-40. DOI: 10.1111/j.1365-2222.2003.01835.x. View

14.

Gill H, Prasad J . Probiotics, immunomodulation, and health benefits. Adv Exp Med Biol. 2008; 606:423-54. DOI: 10.1007/978-0-387-74087-4_17. View

15.

Goldin B, Gorbach S . Clinical indications for probiotics: an overview. Clin Infect Dis. 2008; 46 Suppl 2:S96-100. DOI: 10.1086/523333. View

16.

Kato I, Yokokura T . Suppressive effects of the oral administration of Lactobacillus casei on type II collagen-induced arthritis in DBA/1 mice. Life Sci. 1998; 63(8):635-44. DOI: 10.1016/s0024-3205(98)00315-4. View

17.

Schultz M, Linde H, Lehn N, Zimmermann K, Grossmann J, Falk W . Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res. 2003; 70(2):165-73. DOI: 10.1017/s0022029903006034. View

18.

Baharav E, Mor F, Halpern M, Weinberger A . Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr. 2004; 134(8):1964-9. DOI: 10.1093/jn/134.8.1964. View

19.

Malin M, Verronen P, Korhonen H, Syvaoja E, Salminen S, Mykkanen H . Dietary therapy with Lactobacillus GG, bovine colostrum or bovine immune colostrum in patients with juvenile chronic arthritis: evaluation of effect on gut defence mechanisms. Inflammopharmacology. 1997; 5(3):219-36. DOI: 10.1007/s10787-997-0001-1. View

20.

Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, Tuckova L, Cukrowska B, Lodinova-Zadnikova R . Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett. 2004; 93(2-3):97-108. DOI: 10.1016/j.imlet.2004.02.005. View